NYSE:ZTS - Zoetis Stock Price, Price Target & More

Get Started

$84.88 +0.50 (+0.59 %)

(As of 05/23/2018 04:00 PM ET)

Previous Close$84.38

Today's Range$83.74 - $85.00

52-Week Range$59.50 - $86.38

Volume1.74 million shs

Average Volume2.70 million shs

Market Capitalization$41.31 billion

P/E Ratio35.37

Dividend Yield0.59%

Beta0.97

About Zoetis (NYSE:ZTS)

Zoetis Inc. discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers other product categories, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices, diagnostics, and genetics. It markets its products to veterinarians, livestock producers, and people who raise and care for farm and companion animals through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNYSE:ZTS

CUSIP98978V10

Webwww.zoetis.com

Phone973-822-7000

Debt

Debt-to-Equity Ratio2.51

Current Ratio4.27

Quick Ratio2.83

Price-To-Earnings

Trailing P/E Ratio35.37

Forward P/E Ratio27.74

P/E Growth1.88

Sales & Book Value

Annual Sales$5.31 billion

Price / Sales7.74

Cash Flow$2.9108 per share

Price / Cash29.16

Book Value$4.08 per share

Price / Book20.80

Profitability

EPS (Most Recent Fiscal Year)$2.40

Net Income$864 million

Net Margins17.97%

Return on Equity68.51%

Return on Assets15.00%

Miscellaneous

Employees9,200

Outstanding Shares483,860,000

Zoetis (NYSE:ZTS) Frequently Asked Questions

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis declared a quarterly dividend on Tuesday, May 15th. Stockholders of record on Friday, July 20th will be given a dividend of $0.126 per share on Tuesday, September 4th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.59%. The ex-dividend date of this dividend is Thursday, July 19th. View Zoetis' Dividend History.

How were Zoetis' earnings last quarter?

Zoetis (NYSE:ZTS) announced its earnings results on Wednesday, May, 2nd. The company reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.06. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.35 billion. Zoetis had a net margin of 17.97% and a return on equity of 68.51%. The business's revenue was up 11.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.53 earnings per share. View Zoetis' Earnings History.

When is Zoetis' next earnings date?

Zoetis is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Zoetis.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis issued an update on its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share (EPS) guidance of $2.96-3.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.04. The company issued revenue guidance of $5.675-5.800 billion, compared to the consensus revenue estimate of $5.74 billion.

What price target have analysts set for ZTS?

18 analysts have issued 1 year price targets for Zoetis' shares. Their forecasts range from $62.00 to $98.00. On average, they anticipate Zoetis' stock price to reach $82.6471 in the next year. View Analyst Ratings for Zoetis.

What are Wall Street analysts saying about Zoetis stock?

Here are some recent quotes from research analysts about Zoetis stock:

1. Cantor Fitzgerald analysts commented, "We rate ZTS as 12-month price target of $98. Given the company’s durable business model and the positive outlook for macro factors, we think the multiple will hold and upwards earnings revisions should drive shares higher. Valuation Summary We use a blend of DCF and multiples analysis (EV/EBITDA) to get to our 12- month price target of $98." (5/16/2018)
2. According to Zacks Investment Research, "Zoetis faces stiff competition from other animal health medicines and vaccines companies like Merck Animal Health (the animal health division of Merck), Elanco (the animal health division of Eli Lilly), Bayer Animal Health (the animal health division of Bayer) and Boehringer Ingelheim Animal Health (the animal health division of Boehringer Ingelheim). Disease outbreak among animals is a material cause of concern for Zoetis’ livestock products.In addition, companion animal health products are often directly prescribed and dispensed by veterinarians. The swine business is being impacted by competition for Fostera. These competitive pressures could adversely affect the company’s business and operating results. However, shares of the company have outperformed the industry in the last six months." (1/13/2018)

Who are some of Zoetis' key competitors?

Some companies that are related to Zoetis include Merck & Co. (MRK), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY) and Regeneron (REGN).

Who are Zoetis' key executives?

Zoetis' management team includes the folowing people:

Mr. Juan Ramón Alaix, CEO & Director (Age 67)
Mr. Glenn C. David, Exec. VP & CFO (Age 46)
Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 57)
Mr. Clinton A. Lewis Jr., EVP and Pres of International Ops., Commercial Devel., Global Genetics & Aquatic Health (Age 51)
Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 47)

Has Zoetis been receiving favorable news coverage?

Media coverage about ZTS stock has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zoetis earned a media sentiment score of 0.12 on Accern's scale. They also gave news stories about the company an impact score of 45.86 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.49%), Polen Capital Management LLC (1.85%), Massachusetts Financial Services Co. MA (1.66%), Northern Trust Corp (1.23%), Wells Fargo & Company MN (1.20%) and American Century Companies Inc. (1.07%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Heidi C Chen, Kristin C Peck, Michael B Mccallister, Roman Trawicki and Roxanne Lagano. View Institutional Ownership Trends for Zoetis.

Which institutional investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including Independent Franchise Partners LLP, Winslow Capital Management LLC, Thrivent Financial for Lutherans, Eaton Vance Management, Cantillon Capital Management LLC, Massachusetts Financial Services Co. MA, Federated Investors Inc. PA and Franklin Resources Inc.. Company insiders that have sold Zoetis company stock in the last year include Heidi C Chen, Kristin C Peck, Roman Trawicki and Roxanne Lagano. View Insider Buying and Selling for Zoetis.

Which institutional investors are buying Zoetis stock?

ZTS stock was purchased by a variety of institutional investors in the last quarter, including Polen Capital Management LLC, BlackRock Inc., Amundi Pioneer Asset Management Inc., Royal Bank of Canada, Wells Fargo & Company MN, Intermede Investment Partners Ltd, Prudential Financial Inc. and Westfield Capital Management Co. LP. View Insider Buying and Selling for Zoetis.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $84.88.

How big of a company is Zoetis?

Zoetis has a market capitalization of $41.31 billion and generates $5.31 billion in revenue each year. The company earns $864 million in net income (profit) each year or $2.40 on an earnings per share basis. Zoetis employs 9,200 workers across the globe.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]

MarketBeat Community Rating for Zoetis (ZTS)

Community Ranking:		3.1 out of 5 ( )
Outperform Votes:		522 (Vote Outperform)
Underperform Votes:		312 (Vote Underperform)
Total Votes:		834

MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Zoetis (NYSE:ZTS) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

18 Wall Street analysts have issued ratings and price targets for Zoetis in the last 12 months. Their average twelve-month price target is $82.6471, suggesting that the stock has a possible downside of 2.63%. The high price target for ZTS is $98.00 and the low price target for ZTS is $62.00. There are currently 7 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.61	2.61	2.72	2.59
Ratings Breakdown:	0 Sell Rating(s) 7 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 7 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 5 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$82.6471	$81.5294	$79.6471	$67.4375
Price Target Upside:	2.63% downside	5.17% downside	0.10% downside	5.11% downside

Zoetis (NYSE:ZTS) Consensus Price Target History

Price Target History for Zoetis (NYSE:ZTS)

Zoetis (NYSE:ZTS) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/16/2018	BMO Capital Markets	Reiterated Rating	Hold	$80.00	Low
5/16/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$98.00	Low
4/25/2018	Craig Hallum	Reiterated Rating	Buy	$87.00 ➝ $94.00	Low
4/19/2018	Hilliard Lyons	Downgrade	Neutral		Low
4/19/2018	Citigroup	Reiterated Rating	Buy ➝ Buy	$85.00 ➝ $98.00	Low
4/13/2018	Jefferies Group	Reiterated Rating	Buy	$96.00	Low
4/5/2018	Credit Suisse Group	Boost Price Target	Outperform ➝ Outperform	$83.00 ➝ $89.00	Low
3/19/2018	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$70.00	Low
2/17/2018	Barclays	Set Price Target	Hold	$77.00	Medium
2/16/2018	Deutsche Bank	Boost Price Target	Hold ➝ Hold	$76.00 ➝ $78.00	Low
2/16/2018	Piper Jaffray Companies	Set Price Target	Buy	$88.00	Low
2/16/2018	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$84.00 ➝ $86.00	Medium
2/16/2018	Bank of America	Boost Price Target	Buy	$80.00 ➝ $87.00	Medium
2/15/2018	Cowen	Set Price Target	Buy	$85.00	Medium
11/24/2017	UBS	Reiterated Rating	Buy ➝ Neutral		N/A
8/7/2017	Goldman Sachs Group	Reiterated Rating	Neutral ➝ Neutral	$62.00	Low
5/30/2017	Argus	Reiterated Rating	Buy	$60.00 ➝ $69.00	Low
5/26/2017	CL King	Initiated Coverage	Buy ➝ Buy	$71.00	Low
2/16/2017	Guggenheim	Boost Price Target	Buy	$60.00 ➝ $65.00	N/A
2/16/2017	Off Wall Street	Reiterated Rating	Strong Sell	$35.00	N/A
11/3/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold	$53.00	N/A

(Data available from 5/23/2016 forward)

Zoetis (NYSE:ZTS) Earnings History and Estimates Chart

Earnings by Quarter for Zoetis (NYSE:ZTS)

Zoetis (NYSE:ZTS) Earnings Estimates

2018 EPS Consensus Estimate: $3.03
2019 EPS Consensus Estimate: $3.37

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$0.70	$0.71	$0.71
Q2 2018	1	$0.72	$0.72	$0.72
Q3 2018	1	$0.78	$0.78	$0.78
Q4 2018	1	$0.82	$0.82	$0.82
Q1 2019	1	$0.78	$0.78	$0.78
Q2 2019	1	$0.80	$0.80	$0.80
Q3 2019	1	$0.88	$0.88	$0.88
Q4 2019	1	$0.91	$0.91	$0.91

Zoetis (NYSE ZTS) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/6/2018		$0.71					N/A
5/2/2018	Q1 2018	$0.69	$0.75	$1.3473 billion	$1.3660 billion	View	N/A
2/15/2018	Q4 2017	$0.66	$0.69	$1.4034 billion	$1.46 billion	View	N/A
11/2/2017	Q3 2017	$0.63	$0.65	$1.3206 billion	$1.3470 billion	View	N/A
8/8/2017	Q2 2017	$0.53	$0.5280	$1.2660 billion	$1.2690 billion	View	Listen
5/4/2017	Q1 2017	$0.48	$0.53	$1.1967 billion	$1.2310 billion	View	Listen
2/16/2017	Q416	$0.45	$0.47	$1.28 billion	$1.30 billion	View	N/A
11/2/2016	Q316	$0.46	$0.52	$1.22 billion	$1.20 billion	View	N/A
8/3/2016	Q216	$0.44	$0.49	$1.17 billion	$1.20 billion	View	N/A
5/4/2016	Q116	$0.41	$0.48	$1.10 billion	$1.20 billion	View	N/A
2/16/2016	Q415	$0.39	$0.43	$1.25 billion	$1.30 billion	View	Listen
11/3/2015	Q315	$0.40	$0.50	$1.18 billion	$1.20 billion	View	N/A
8/4/2015	Q215	$0.38	$0.43	$1.12 billion	$1.20 billion	View	N/A
5/5/2015	Q115	$0.37	$0.41	$1.11 billion	$1.10 billion	View	N/A
2/11/2015	Q414	$0.36	$0.40	$1.27 billion	$1.30 billion	View	N/A
11/4/2014	Q314	$0.37	$0.41	$1.16 billion	$1.20 billion	View	N/A
8/5/2014	Q2 2014	$0.39	$0.38	$1.1640 billion	$1.1580 billion	View	N/A
5/6/2014	Q114	$0.37	$0.38	$1.13 billion	$1.10 billion	View	N/A
2/11/2014	Q413	$0.34	$0.36	$1.21 billion	$1.25 billion	View	N/A
11/5/2013	Q313	$0.34	$0.34	$1.07 billion	$1.10 billion	View	N/A
8/6/2013	Q2 2013	$0.36	$0.36	$1.13 billion	$1.1140 billion	View	N/A
4/30/2013	Q1 2013	$0.27	$0.36	$1.24 billion	$1.09 billion	View	N/A
3/28/2013	Q4 2012	$0.34	$0.07			View	N/A

(Earnings results data provided by Zacks Investment Research)

Zoetis (NYSE:ZTS) Dividend Information

Zoetis pays an annual dividend of $0.50 per share, with a dividend yield of 0.59%. ZTS's next quarterly dividend payment will be made on Tuesday, September 4. The company has grown its dividend for the last 4 consecutive years and is increasing its dividend by an average of 13.40% each year. Zoetis pays out 20.83% of its earnings out as a dividend.

Next Dividend:	9/4/2018
Annual Dividend:	$0.50
Dividend Yield:	0.59%
Dividend Growth:	13.40% (3 Year Average)
Payout Ratio(s):	20.83% (Trailing 12 Months of Earnings) 16.34% (Based on This Year's Estimates) 14.53% (Based on Next Year's Estimates) 17.18% (Based on Cash Flow)
Track Record:	4 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Zoetis (NYSE:ZTS)

Zoetis (NYSE:ZTS) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/15/2018	quarterly	$0.1260	0.6%	7/19/2018	7/20/2018	9/4/2018
2/14/2018	quarterly	$0.1260	0.68%	4/19/2018	4/20/2018	6/1/2018
12/12/2017	quarterly	$0.1260	0.7%	1/18/2018	1/19/2018	3/1/2018
10/5/2017	quarterly	$0.1050	0.66%	11/8/2017	11/9/2017	12/1/2017
5/12/2017	quarterly	$0.1050	0.7%	6/13/2017	6/15/2017	9/1/2017
2/15/2017	quarterly	$0.1050	0.76%	4/4/2017	4/6/2017	6/1/2017
12/6/2016	quarterly	$0.1050	0.82%	1/18/2017	1/20/2017	3/1/2017
10/7/2016	quarterly	$0.0950	0.73%	11/1/2016	11/3/2016	12/1/2016
5/13/2016	quarterly	$0.0950	0.82%	6/28/2016	6/30/2016	8/30/2016
2/22/2016	quarterly	$0.0950	0.89%	4/5/2016	4/7/2016	6/1/2016
12/17/2015	quarterly	$0.0950	0.81%	1/19/2016	1/21/2016	3/1/2016
10/2/2015	quarterly	$0.0830	0.77%	11/3/2015	11/5/2015	12/1/2015
7/22/2015	quarterly	$0.0830	0.66%	8/11/2015	8/13/2015	9/1/2015
3/2/2015	quarterly	$0.0830	0.7%	4/7/2015	4/9/2015	6/2/2015
12/18/2014	quarterly	$0.0830	0.77%	1/20/2015	1/22/2015	3/3/2015
10/2/2014	quarterly	$0.0720	0.76%	11/3/2014	11/5/2014	12/2/2014
7/31/2014	quarterly	$0.0720	0.88%	8/18/2014	8/20/2014	9/2/2014
3/26/2014	quarterly	$0.0720	0.98%	4/23/2014	4/27/2014	6/2/2014
12/19/2013	quarterly	$0.0720	0.89%	1/28/2014	1/30/2014	3/4/2014
9/12/2013	quarterly	$0.0650	0.84%	10/30/2013	11/1/2013	12/2/2013
6/20/2013	quarterly	$0.0650			8/1/2013	9/2/2013
3/29/2013	special	$0.0650		4/29/2013	5/1/2013	6/6/2013
3/28/2013	quarterly	$0.0650			5/1/2013	6/6/2013

(Data available from 1/1/2013 forward)

Zoetis (NYSE ZTS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.35%
Institutional Ownership Percentage: 91.15%

Insider Trading History for Zoetis (NYSE:ZTS)

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Zoetis (NYSE ZTS) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/1/2018	Kristin C Peck	Insider	Sell	4,877	$83.46	$407,034.42	42,652
3/16/2018	Heidi C Chen	Insider	Sell	7,383	$84.71	$625,413.93	20,162
3/9/2018	Roman Trawicki	Insider	Sell	8,568	$83.10	$712,000.80	11,457
2/23/2018	Roman Trawicki	Insider	Sell	23,885	$82.00	$1,958,570.00
2/21/2018	Roxanne Lagano	EVP	Sell	35,663	$81.02	$2,889,416.26	49,919
2/20/2018	Heidi C Chen	Insider	Sell	37,453	$81.02	$3,034,442.06
5/12/2017	Catherine A Knupp	Insider	Sell	5,785	$60.16	$348,025.60	24,415
11/22/2016	Kristin C Peck	Insider	Sell	10,092	$49.55	$500,058.60	22,768
11/8/2016	Roxanne Lagano	Insider	Sell	9,797	$50.43	$494,062.71	8,063
9/6/2016	Michael B Mccallister	Director	Buy	2,000	$51.34	$102,680.00
9/2/2016	Andrew Fenton	Insider	Sell	13,870	$51.25	$710,837.50	17,719
9/1/2016	Heidi C Chen	Insider	Sell	32,097	$50.98	$1,636,305.06	46,060
5/9/2016	Pershing Square Capital Manage	Director	Sell	16,850,000	$46.55	$784,367,500.00
8/8/2013	Michael Mccallister	Director	Buy	7,000	$31.35	$219,450.00
2/6/2013	Frank A Damelio	Director	Buy	5,000	$26.00	$130,000.00
2/6/2013	Sandra J Beaty	EVP	Buy	2,000	$26.00	$52,000.00

(Data available from 1/1/2013 forward)

Zoetis (NYSE ZTS) News Headlines

Source:

Date	Headline
	Is Zoetis Inc’s (NYSE:ZTS) 49.27% ROE Strong Compared To Its Industry? finance.yahoo.com - May 23 at 9:21 AM
	FY2018 Earnings Estimate for Zoetis (ZTS) Issued By Cantor Fitzgerald www.americanbankingnews.com - May 23 at 7:05 AM
	Zoetis to Participate in the Stifel 2018 Dental & Veterinary Conference www.businesswire.com - May 22 at 9:28 AM
	Zoetis Agrees To Buy Abaxis In $2.0 Bln Deal www.nasdaq.com - May 18 at 10:58 AM
	Zoetis Inc. (ZTS) PT Raised to $82 at BMO Capital; Abaxis Deal Strong But Doesn't Change Thesis www.streetinsider.com - May 17 at 4:14 PM
	Abaxis (ABAX) to be Acquired by Zoetis, Shares All-Time High finance.yahoo.com - May 17 at 4:14 PM
	Company News For May 17, 2018 finance.yahoo.com - May 17 at 4:14 PM
	[$$] Zoetis to Buy Veterinary-Diagnostics Company Abaxis for $2 Billion finance.yahoo.com - May 17 at 9:52 AM
	Zoetis (ZTS) Expected to Announce Quarterly Sales of $1.39 Billion www.americanbankingnews.com - May 17 at 4:52 AM
	Zoetis (ZTS) Receives "Hold" Rating from BMO Capital Markets www.americanbankingnews.com - May 16 at 4:50 PM
	Dow Closes Higher as Wall Street Weighs Rising Rates finance.yahoo.com - May 16 at 4:20 PM
	Zoetis Inc. -- Moody's says Zoetis' acquisition of Abaxis is credit negative finance.yahoo.com - May 16 at 4:20 PM
	Zoetis (ZTS) Rating Reiterated by Cantor Fitzgerald www.americanbankingnews.com - May 16 at 3:21 PM
	M&A News: Abaxis Inc Shares Soar on $2 Billion Zoetis Deal investorplace.com - May 16 at 12:21 PM
	M&A News: Abaxis Inc Shares Soar on $2 Billion Zoetis Deal investorplace.com - May 16 at 12:18 PM
	BRIEF-Zoetis To Acquire Abaxis for about $2 Bln In Aggregate www.reuters.com - May 16 at 10:10 AM
	Zoetis Declares Third Quarter 2018 Dividend www.businesswire.com - May 16 at 10:10 AM
	Stocks Trade Modestly Higher Amid Rising Rates finance.yahoo.com - May 16 at 10:10 AM
	Zoetis to buy veterinary diagnostics firm Abaxis for $1.9 billion www.cnbc.com - May 16 at 8:10 AM
	Zoetis to acquire Abaxis for $2B seekingalpha.com - May 16 at 7:52 AM
	Zoetis (ZTS) Declares Quarterly Dividend of $0.13 www.americanbankingnews.com - May 15 at 5:58 PM
	BRIEF-Anatara Lifesciences Announces Exclusive Global License Agreement With Zoetis www.reuters.com - May 15 at 10:15 AM
	Anatara Announces Exclusive Global License Agreement with Zoetis www.businesswire.com - May 15 at 10:15 AM
	$0.71 Earnings Per Share Expected for Zoetis (ZTS) This Quarter www.americanbankingnews.com - May 15 at 3:26 AM
	Zoetis Reaches Analyst Target Price www.forbes.com - May 14 at 4:18 PM
	Head to Head Contrast: Zoetis (ZTS) and Its Rivals www.americanbankingnews.com - May 13 at 5:15 PM
	Critical Contrast: Zoetis (ZTS) vs. The Competition www.americanbankingnews.com - May 13 at 3:16 AM
	Zoetis (ZTS) Expected to Post Q4 2018 Earnings of $0.82 Per Share www.americanbankingnews.com - May 7 at 4:16 AM
	Research Analysts Set Expectations for Zoetis' Q3 2018 Earnings (ZTS) www.americanbankingnews.com - May 4 at 7:26 AM
	Kristin C. Peck Sells 4,877 Shares of Zoetis (ZTS) Stock www.americanbankingnews.com - May 3 at 7:54 PM
	Edited Transcript of ZTS earnings conference call or presentation 2-May-18 12:30pm GMT finance.yahoo.com - May 3 at 9:35 AM
	Zoetis Inc. www.streetinsider.com - May 2 at 4:18 PM
	Zoetis (ZTS) Beats on Q1 Earnings & Sales, Retains '18 View www.zacks.com - May 2 at 4:18 PM
	Zoetis (ZTS) Beats on Q1 Earnings & Sales, Retains '18 View finance.yahoo.com - May 2 at 4:18 PM
	Zoetis (ZTS) Posts Earnings Results www.americanbankingnews.com - May 2 at 11:42 AM
	BRIEF-Zoetis Announces Q1 Earnings Per Share $0.72 www.reuters.com - May 2 at 9:37 AM
	Zoetis profit up 48%, buoyed by tax benefit www.marketwatch.com - May 2 at 9:37 AM
	Zoetis Tops Quarterly Estimates But 2018 Earnings View Soft At Midpoint finance.yahoo.com - May 2 at 9:37 AM
	Zoetis: 1Q Earnings Snapshot finance.yahoo.com - May 2 at 9:37 AM
	Zoetis (ZTS) Updates FY18 Earnings Guidance www.americanbankingnews.com - May 2 at 9:15 AM
	Zoetis Q1 revenues up 11%; non-GAAP EPS up 42%; reiterates guidance seekingalpha.com - May 2 at 8:55 AM
	Zoetis (ZTS) call put ratio 1 call to 6 puts into Q1 www.streetinsider.com - May 1 at 4:14 PM
	Forbes Names Zoetis One of America’s Best Employers for Third Year in a Row finance.yahoo.com - May 1 at 4:13 PM
	Zoetis (ZTS) Given a $90.00 Price Target by Cantor Fitzgerald Analysts www.americanbankingnews.com - May 1 at 10:01 AM
	Zoetis (ZTS) Receives Consensus Recommendation of "Buy" from Brokerages www.americanbankingnews.com - April 30 at 3:40 PM
	Zoetis (ZTS) Gears Up for Q1 Earnings: What's in Store? www.nasdaq.com - April 30 at 10:40 AM
	Zoetis (ZTS) Gears Up for Q1 Earnings: What's in Store? finance.yahoo.com - April 30 at 10:39 AM
	Zacks: Brokerages Anticipate Zoetis (ZTS) Will Post Quarterly Sales of $1.33 Billion www.americanbankingnews.com - April 29 at 2:52 AM
	Zacks: Brokerages Expect Zoetis (ZTS) to Announce $0.70 EPS www.americanbankingnews.com - April 27 at 3:18 PM
	BRIEF-Zoetis Inc To Expand Animal Vaccine Research And Manufacturing In Suzhou, China www.reuters.com - April 26 at 9:41 AM

Zoetis (NYSE:ZTS) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Zoetis (NYSE:ZTS) Income Statement, Balance Sheet and Cash Flow Statement

Zoetis (NYSE ZTS) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff